Navigation Links
UC Davis bench-to-bedside research: Promising treatment in clinical trials
Date:3/26/2009

DAVIS, CALIF.A new drug developed at the University of California, Davis to treat diabetes, hypertension and inflammatory has entered Phase II of human clinical trials to evaluate its efficacy.

The compound, a soluble epoxide hydrolase enzyme (s-EH) inhibitor, is "a first-in-class drug which may treat a suite of major cardiovascular and metabolic diseases," said entomologist Bruce Hammock, who with UC Berkeley cell biologist Sarjeet Gill discovered the enzyme in 1969 while researching fundamental insect biology.

"This is one of the few examples of basic research in an academic laboratory moving through target validation and compound optimization all the way to the clinic," he said.

The enzyme is involved in the metabolism of arachidonic acid, a key signaling molecule implicated in diabetes, hypertension and inflammatory disorders. "It's an enzyme in the same arachidonic biochemical pathway where many other common pharmaceuticals such as aspirin, Advil, Aleve, Ibuprofen, Motrin and other are active," he said.

Phase 1 evaluated the safety, safe dosage range and side effects of the drug candidate. It then entered Phase IIa.

UC Davis physicians and scientists praised the new drug as promising. Nephrologist and cell biologist Robert Weiss of the UC Davis Health System said the drug could lead to important health implications for patients with type 2 diabetes, a chronic disease affecting an estimated 23.6 million children and adults in the United States.

"Both diabetes and hypertension are often associated with vascular inflammation as is atherosclerosis," Weiss said. "Last year we demonstrated that these compounds dramatically reduce atherosclerosis problem in obese mice."

"These compounds appear useful in a variety of cardiovascular disorders," said biochemist and food scientist Bruce German, UC Davis professor of food science and technology.

"Diabetes and high blood pressure commonly
'/>"/>

Contact: Kathy Keatley Garvey
kegarvey@ucdavis.edu
530-754-6894
University of California - Davis
Source:Eurekalert  

Page: 1 2 3 4 5

Related biology news :

1. UC Davis research shows that newly discovered drug reduces heart enlargement
2. UC Davis researchers find molecule that targets brain tumors
3. UC Davis discovery offers hope for treating kidney cancer
4. UC Davis team refines cancer treatments to reduce potential nerve damage
5. UC Davis researchers exploring gene therapy to fight AIDS
6. UC Davis researchers discover Achilles heel in pancreatic cancer
7. UC Davis researchers discover a key to aggressive breast cancer
8. UC Davis chemical ecologist wins major award
9. UC Davis researchers discover new drug target for inflammatory disease
10. UC Davis researchers define characteristics, treatment options for XXYY syndrome
11. UC Davis researcher leads climate-change discovery
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
UC Davis bench-to-bedside research: Promising treatment in clinical trials
(Date:8/21/2014)... study of American singles found that during sex ... orgasm rates. On average, men experience orgasm 85.1 ... making little difference. For women, however, orgasm occurrence ... 62.9 percent of the time during sex with ... with women,s sexual orientation, with lesbian women experiencing ...
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- LiveScan ... has agreed to a partnership with Gabriel Health ... fastest growing Certified Nursing Assistant preparatory ... Institute  an exclusive member of Binary,s LiveScan service ... Biometrics will improve its service capabilities by ...
(Date:8/21/2014)... consists of radiations in the 3.3 to 4.4 nanometre ... biological tissues. New theoretical findings show that it is ... These could be the basis of an optimal technique ... or to be used in high-precision spectroscopy. Now, a ... efficiently generate the harmonic radiationswhich are multiples of an ...
Breaking Biology News(10 mins):Orgasm rates for single women less predictable than men's, vary by sexual orientation 2Orgasm rates for single women less predictable than men's, vary by sexual orientation 3Orgasm rates for single women less predictable than men's, vary by sexual orientation 4LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3Water window imaging opportunity 2
... respiratory pathogen Pseudomonas aeruginosa takes an ordinary protein ... molecules to turn it into a key for gaining access ... 7 in mBio , the online open-access journal of ... of Medicine, the University of Virginia, and Universidad de las ...
... in cases of lung edema, or fluid in the lungs, not ... believed, but they are also allowing water to pump in. ... it was previously believed that this pump mechanism just stopped when ... St. Michael,s Hospital. "But we,ve found not only do they stop ...
... Scientists from the Luxembourg Centre for Systems Biomedicine (LCSB) ... cells in the brain can produce a substance that ... had assumed that only certain fungi produced itaconic acid. ... the Metabolomics Group at LCSB, and Dr. Alessandro Michelucci ...
Cached Biology News:Pathogen turns protein into a virulence factor in 1 easy step 2Pathogen turns protein into a virulence factor in 1 easy step 3LCSB discovers endogenous antibiotic in the brain 2
(Date:8/22/2014)... a study published today (August 22nd), in the ... the Champalimaud Neuroscience Programme establish the effect of ... of advanced genetic and optical techniques., "Serotonin is ... a wide range of brain functions, from the ... of complex emotional behaviours, This neurotransmitter is also ...
(Date:8/22/2014)... August 22, 2014 Ophthalmic drug ... interesting and challenging endeavors as the anatomy, physiology ... properties to the foreign substances. Ocular drug delivery ... self medication and minimal use of needles; also ... drugs and provides specific targeting within the ocular ...
(Date:8/22/2014)... Research and Markets has announced ... Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) ... offering. The global molecular biology enzymes ... is expected to grow at a CAGR of 13.74% ... kits, & reagents find applications in a large number ...
(Date:8/22/2014)... August 22, 2014 The identification ... organisms can be accelerated by exome sequencing. Built ... technologies, the custom SeqCap EZ Developer system has ... Mr. Watson will additionally present how he achieved ... available human and mouse exome kits. With over ...
Breaking Biology Technology:From happiness to pain: Understanding serotonin's function 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Ocular Drug Delivery Technologies Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 2Global Molecular Biology Enzymes, Kits, & Reagents (Cloning, Epigenetics, PCR, Restriction Digestion, Sequencing) Market - Forecast to 2018 3Efficient Identification of Protein-Coding Variants in a Model Organism Through Exome Sequencing, New Webinar Hosted by Xtalks 2
... 5 NeoGenomics, Inc. (NASD OTC Bulletin Board: NGNM), an operator ... fourth quarter and full-year ended December 31, 2008. Fourth Quarter ... Revenue of $5.9 million, an increase of 56% ... 17.2% sequential increase in revenues in Q4 08 vs. Q3 08 , ...
... Rojas to Director of Global Business Development Operations , ... ... a leading provider of multilingual localization, testing and outsourced software development ... Vice President of Global Business Development and Helena Rojas to Director ...
... March 4 Osteotech, Inc. (Nasdaq: ... of biologic products for regenerative healing, today reported ... year ended December 31, 2008."The last twelve months ... entire team worked diligently to execute our corporate ...
Cached Biology Technology:NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 2NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 3NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 4NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 5NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 6NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 7NeoGenomics Announces Fourth Quarter and Full Year 2008 Financial Results 8Localization and Translation Leader CSOFT International Ltd. Recognizes Efforts of Two Key Members of its Business Development Team 2Localization and Translation Leader CSOFT International Ltd. Recognizes Efforts of Two Key Members of its Business Development Team 3Osteotech Reports Fourth Quarter and Full Year 2008 Financial Results; Company Plans Three Product Launches and Unveilings in 2009; Will Provide 2009 Guidance During Conference Call on March 5, 2009 at 9:00 a.m. EST 2Osteotech Reports Fourth Quarter and Full Year 2008 Financial Results; Company Plans Three Product Launches and Unveilings in 2009; Will Provide 2009 Guidance During Conference Call on March 5, 2009 at 9:00 a.m. EST 3Osteotech Reports Fourth Quarter and Full Year 2008 Financial Results; Company Plans Three Product Launches and Unveilings in 2009; Will Provide 2009 Guidance During Conference Call on March 5, 2009 at 9:00 a.m. EST 4Osteotech Reports Fourth Quarter and Full Year 2008 Financial Results; Company Plans Three Product Launches and Unveilings in 2009; Will Provide 2009 Guidance During Conference Call on March 5, 2009 at 9:00 a.m. EST 5Osteotech Reports Fourth Quarter and Full Year 2008 Financial Results; Company Plans Three Product Launches and Unveilings in 2009; Will Provide 2009 Guidance During Conference Call on March 5, 2009 at 9:00 a.m. EST 6Osteotech Reports Fourth Quarter and Full Year 2008 Financial Results; Company Plans Three Product Launches and Unveilings in 2009; Will Provide 2009 Guidance During Conference Call on March 5, 2009 at 9:00 a.m. EST 7